Parnax Lab Ltd
PARNAXLABParnax Lab Ltd
PARNAXLAB
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 16.41 | 2.71 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.53 | 6.56 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Parnax Lab is principally engaged in the business activities of manufacturing and export of pharmaceutical formulations
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 71.92 | 95.18 | 106.69 | 110.89 | 95.97 | 90.27 | 163.36 | 168.38 | 189.53 | 197.25 | ||||||||||
Raw Materials | 37.10 | 58.02 | 62.23 | 59.93 | 54.43 | 48.49 | 101.47 | 101.31 | 118.31 | 168.21 | ||||||||||
| Power & Fuel Cost | 2.11 | 3.27 | 2.99 | 3.13 | 4.12 | 4.29 | 5.24 | 5.37 | 6.37 | |||||||||||
| Employee Cost | 7.46 | 9.22 | 11.68 | 13.06 | 14.08 | 13.68 | 17.43 | 20.05 | 23.72 | |||||||||||
| Selling & Administrative Expenses | 4.32 | 4.49 | 8.09 | 12.36 | 6.74 | 4.86 | 6.75 | 8.33 | 8.54 | |||||||||||
| Operating & Other expenses | 10.26 | 6.79 | 10.61 | 10.08 | 9.51 | 8.80 | 9.11 | 9.56 | 8.23 | |||||||||||
EBITDA | 10.67 | 13.39 | 11.09 | 12.33 | 7.09 | 10.15 | 23.36 | 23.76 | 24.36 | 29.04 | ||||||||||
| Depreciation/Amortization | 2.90 | 3.75 | 3.74 | 3.82 | 4.46 | 5.16 | 5.87 | 6.53 | 6.96 | 7.39 | ||||||||||
| PBIT | 7.77 | 9.64 | 7.35 | 8.51 | 2.63 | 4.99 | 17.49 | 17.23 | 17.40 | 21.65 | ||||||||||
| Interest & Other Items | 4.29 | 4.92 | 4.32 | 3.89 | 4.60 | 5.08 | 5.23 | 4.95 | 5.35 | 5.64 | ||||||||||
| PBT | 3.48 | 4.72 | 3.03 | 4.62 | -1.97 | -0.09 | 12.26 | 12.28 | 12.05 | 16.01 | ||||||||||
| Taxes & Other Items | 0.97 | 1.03 | 1.97 | 1.32 | 0.95 | 0.28 | 4.03 | 3.66 | 2.44 | 4.19 | ||||||||||
| Net Income | 2.51 | 3.69 | 1.06 | 3.30 | -2.92 | -0.37 | 8.23 | 8.62 | 9.61 | 11.82 | ||||||||||
| EPS | 2.95 | 4.34 | 1.25 | 3.88 | -3.43 | -0.44 | 8.98 | 8.09 | 8.37 | 10.29 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Parnax Lab Ltd | 20.19 | 2.71 | — |
| Sun Pharmaceutical Industries Ltd | 45.35 | 6.47 | 0.75% |
| Cipla Ltd | 28.51 | 4.38 | 0.89% |
| Torrent Pharmaceuticals Ltd | 68.45 | 16.54 | 0.84% |
Price Comparison
Compare PARNAXLAB with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
PARNAXLAB has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNet profit of Parnax Lab rose 82.35% to Rs 3.41 crore in the quarter ended September 2024 as against Rs 1.87 crore during the previous quarter ended September 2023. Sales rose 13.49% to Rs 48.36 crore in the quarter ended September 2024 as against Rs 42.61 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales48.3642.61 13 OPM %14.9712.41 - PBDT6.814.08 67 PBT4.872.34 108 NP3.411.87 82 Powered by Capital Market - Live
Parnax Lab will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
Parnax Lab announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
Net profit of Parnax Lab rose 19.88% to Rs 3.98 crore in the quarter ended June 2024 as against Rs 3.32 crore during the previous quarter ended June 2023. Sales rose 2.83% to Rs 50.12 crore in the quarter ended June 2024 as against Rs 48.74 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales50.1248.74 3 OPM %17.2013.34 - PBDT7.235.58 30 PBT5.403.98 36 NP3.983.32 20 Powered by Capital Market - Live
Parnax Lab will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live
Parnax Lab Consolidated March 2023 Net Sales at Rs 40.91 crore, down 14.62% Y-o-Y
Parnax Lab Consolidated December 2020 Net Sales At Rs 24.83 Crore, Down 2.48% Y-o-Y
Parnax Lab Standalone December 2020 Net Sales At Rs 0.68 Crore, Down 68.2% Y-o-Y
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 11.32%, vs industry avg of 9.03%
Constant Market Share
Over the last 5 years, market share stayed at 0.05%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 23.83%, vs industry avg of 15.27%